QUICKLINKS AND VIEW OPITONS
12 serious heart problems deleted from diabetes drug study of rosiglitazone (Avandia), Dr. Gotzsche
Friday, February 13, 2015 5:31 pm Email this article
Prof. Peter Gotzsche, MD notes that the RECORD trial of the diabetes drug rosiglitazone (Avandia) was terribly manipulated by GlaxoSmithKline.
An article published in the New York Times on July 9, 2010 titled, “Caustic Government Report Deals Blow to Diabetes Drug” revealed that Dr. Thomas Marciniak, a reviewer at the US Food and Drug Administration (FDA), found a dozen instances in which patients taking Rosiglitazone (Avandia) suffered serious heart problems that were not counted in the study’s tally of adverse events.
The article also notes that “It [ Rosiglitazone (Avandia) ] has been shown to increase the risks of bone fractures and to cause swelling that can lead to heart failure and eye problems.”
The article also notes that “Dr. Jerome P. Kassirer, a former editor of The New England Journal, said the Record trial raised the question “whether the entire system is corrupt.””
Prof. Peter Gotzsche, MD cofounded the Cochrane Collaboration in 1993.
It is a non-profit organization of scientists around the world who analyze data to try and figure out the truth about drugs and other health topics.
Prof. Peter Gotzsche, MD is the author of “Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare”
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.